Daridorexant for adults with attention deficit hyperactivity disorder (ADHD) and insomnia disorder: An exploratory study
Comprehensive Psychiatry · 2026-06 · 148 · 152700
DOI: 10.1016/j.comppsych.2026.152700 ↗Kurz gefasst
Fachartikel in der Zeitschrift Comprehensive Psychiatry, 2026-06. Verfasst von Giacomo Grassi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Brain Center Firenze, Florence, Italy. Electronic address: giacomograssimd@gmail.com. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Sleep Initiation and Maintenance Disorders, Pyrrolidines, Orexin Receptor Antagonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Idorsia Pharmaceuticals Ltd.
Themen: Schlaf
Abstract (Originalsprache)
BACKGROUND: Insomnia is highly prevalent in adults with Attention-Deficit/Hyperactivity Disorder (ADHD), worsening core symptoms, mood, and cognition. Despite its impact, pharmacological options remain limited. Dual orexin receptor antagonists, such as daridorexant, are a promising yet untested approach in this population. METHODS: In a naturalistic one-month study, 24 adults with ADHD and comorbid insomnia disorder received daridorexant 50 mg nightly. Sleep outcomes were assessed with the Insomnia Severity Index (ISI), Sleep Condition Indicator (SCI), and actigraphy-based measures. Secondary measures included ADHD symptoms (Barkley Adult ADHD Rating Scale-IV, BAARS-IV), cognitive performance (Conners' Continuous Performance Test-3, CPT-3), and mood and anxiety (Symptoms of Depression Questionnaire, SDQ). RESULTS: ISI and SCI scores improved significantly (both p < .001). Actigraphy confirmed longer total sleep time, higher sleep efficiency, and shorter sleep onset latency; after correction, ISI/SCI improvement and longer total sleep time remained significant. Clinically, 62.5% achieved meaningful improvement (≥7-point ISI reduction), 25% partial-to-minimal, and 12.5% no change or worsening; nearly two-thirds reached non-clinical insomnia levels. CPT-3 revealed enhanced sustained attention and response consistency, with further gains in selective attention and reduced impulsivity among responders. BAARS-IV showed overall improvement, with the sluggish cognitive tempo subscale reaching significance. Mood and anxiety improved, and the SDQ appetite/weight subscale decreased significantly even after correction, suggesting reduced perceived appetite or weight. Daridorexant was well tolerated; two participants reported daytime sleepiness or sedation, and one discontinued due to persistent sedation. CONCLUSIONS: In this preliminary sample, daridorexant was associated with improvements in sleep, attention, mood and anxiety in adults with ADHD and insomnia, supporting further controlled trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Brain Center Firenze, Florence, Italy. Electronic address: giacomograssimd@gmail.com.
- Brain Center Firenze, Florence, Italy.
Förderung
- Idorsia Pharmaceuticals Ltd
Zitieren
APA
Grassi, G., Scillitani, E., Moradei, C., & Cecchelli, C. (2026). Daridorexant for adults with attention deficit hyperactivity disorder (ADHD) and insomnia disorder: An exploratory study. Comprehensive Psychiatry, 148, 152700. https://doi.org/10.1016/j.comppsych.2026.152700
Vancouver
Grassi G, Scillitani E, Moradei C, Cecchelli C. Daridorexant for adults with attention deficit hyperactivity disorder (ADHD) and insomnia disorder: An exploratory study. Comprehensive Psychiatry. 2026;148:152700. doi:10.1016/j.comppsych.2026.152700
BibTeX
@article{Grassi2026,
author = {Grassi, Giacomo and Scillitani, Edoardo and Moradei, Corinna and Cecchelli, Chiara},
title = {Daridorexant for adults with attention deficit hyperactivity disorder (ADHD) and insomnia disorder: An exploratory study},
journal = {Comprehensive Psychiatry},
year = {2026},
volume = {148},
pages = {152700},
doi = {10.1016/j.comppsych.2026.152700}
}
EUVIMED